Novartis Nabs FDA Approval for First-of-Its-Kind Drug for Chronic Hives
Novartis drug Rhapsido is now approved as a second-line treatment for chronic spontaneous urticaria, a rare inflammatory skin disease. Additional clinical trials are ongoing to support potential expansion of the twice-daily pill to other immunological disorders.
Thinking with Our Gut: How the Management of GI Conditions is Evolving
Through new diagnostic methods, integrated approaches and innovative management solutions, patients no longer have to live with discomfort. Here are three major ways the GI field is evolving to better care for patients today.
Price Transparency Enforcement Is Still A Shared Responsibility
Despite all the noise around the updates, there’s one area that’s been conspicuously absent this year: enforcement of patient estimate requirements.
The Burgeoning Life Science Ecosystem of North Texas, Anchored by Pegasus Park
At INVEST Digital Health 2025, David Snow, Executive Director of Pegasus Park, discussed building a life science innovation hub and why life science startups at the North Texas campus are more likely to survive, scale, and exit.
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
September has seen a wide range of executive hires, exits, promotions and layoffs across the healthcare industry. For example, Medtronic, Amgen and Kaiser Permanente welcomed new executives. There were also layoffs at organizations including Novo Nordisk and Seattle Children’s.